Navigation Links
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of PROLOR Biotech, Inc. ("PROLOR" or the "Company") (NYSE MKT: PBTH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to OPKO Health, Inc. ("OPKO") (NYSE: OPK).

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Click here to learn more about the investigation http://zlk.9nl.com/prolor-biotech-pbth/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, PROLOR shareholders may elect to receive 0.9951 shares of OPKO for each share of PROLOR they own, representing a value of approximately $7.025 per share. The transaction has a total approximate value of $480 million. The investigation concerns whether the PROLOR Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether OPKO is underpaying for PROLOR stock, thus unlawfully harming PROLOR stockholders. In particular, at least one analyst set a price target for PROLOR  stock at $12.00 per share.

If you own common stock in PROLOR and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/prolor-biotech-pbth/

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
2. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
3. Hadasit Bio-Holdings CEO Letter to Shareholders
4. Medifirst Solutions, Inc. Announces Further Update To Shareholders
5. Letter from Alliqua CEO, Dave Johnston, to Shareholders
6. TPI to Hold 2012 Shareholder Annual Meeting on May 8, 2013 In New York City
7. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
8. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... 16, 2017 Research and Markets ... Global Markets" report to their offering. ... ... biobrick parts, delivery plasmids, chassis organisms, synthetic cells, production ... genome editing, bioinformatics and specialty media) and enabled technologies ...
(Date:2/16/2017)... 16, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, today announced it ... and entered into a $5 million credit facility ... use the capital for general corporate purposes to ... the treatment of serious diseases treated by dermatologists. ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... NEW YORK , Jan. 24, 2017 /PRNewswire/ ... market study of the laboratory use of nuclear ... of 363 experienced end-users and profiled current practices, ... three years, as well as growth and opportunities. ... NMR, Instrument suppliers, NMR instruments, needs and innovation ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
Breaking Biology News(10 mins):